NYSE · DOLE
Dole plc
$13.13-$0.02 (-0.15%)
Dole plc’s quoted price sits in the lower half of its reported 52-week range, 20.76% below the high.
Loading market information…
NASDAQ · CFMS · USD
Stock price, earnings
Quote as of Sep 1, 2023, 07:57 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Conformis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Conformis, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Conformis, Inc., established in Billerica, Massachusetts in 2004, functions as a medical technology enterprise that designs, produces, and commercializes custom-fit medical devices and surgical instruments. Their product portfolio encompasses a variety of personalized knee replacement systems, including iUni and iDuo for addressing unicompartmental or bicompartmental knee osteoarthritis, the iTotal CR for cruciate-retaining total knee procedures, the iTotal PS for posterior-stabilized total knee replacements, as well as the iTotal Identity and Identity Imprint lines. Additionally, the company offers hip replacement options like the Conformis Hip System and Cordera products, and provides iJigs, which are personalized, single-use surgical guides. Conformis distributes these specialized solutions to orthopedic surgeons, hospitals, and other medical facilities through its dedicated sales force, independent representatives, and distributors, serving markets across the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, Oman, Italy, Poland, and other global regions.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 2, 2022 |
| $2.25+12.5% vs estimate |
| $15.42M+9.16% vs estimate |
| Q3 2021 | Nov 3, 2021 | $1.750.0% vs estimate | $14.25M-12.18% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.13-$0.02 (-0.15%)
Dole plc’s quoted price sits in the lower half of its reported 52-week range, 20.76% below the high.
$0.81-$0.00 (-0.44%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.73% below the high.
$0.45$0.00 (0.0%)
Lucira Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.6% below the high.
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
$0.46+$0.00 (+0.22%)
Chembio Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.31% below the high.
$0.14$0.00 (0.0%)
Titan Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.33% below the high.
$1.20+$0.01 (+0.42%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.95% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
